MA34002B1 - Thérapie antivirale - Google Patents

Thérapie antivirale

Info

Publication number
MA34002B1
MA34002B1 MA35145A MA35145A MA34002B1 MA 34002 B1 MA34002 B1 MA 34002B1 MA 35145 A MA35145 A MA 35145A MA 35145 A MA35145 A MA 35145A MA 34002 B1 MA34002 B1 MA 34002B1
Authority
MA
Morocco
Prior art keywords
antiviral therapy
treatment
hiv
aids
combinations
Prior art date
Application number
MA35145A
Other languages
Arabic (ar)
English (en)
Inventor
Mark Richard Underwood
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34002(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA34002B1 publication Critical patent/MA34002B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des combinaisons de composés comprenant des inhibiteurs de l'intégrase du vih et d'autres agents thérapeutiques. Lesdites combinaisons peuvent être utilisées dans le cadre de l'inhibition de la réplication du vih, de la prévention et/ou du traitement de l'infection par le vih et du traitement du sida et/ou du syndrome pré-sida.
MA35145A 2010-01-27 2011-01-24 Thérapie antivirale MA34002B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
PCT/US2011/022219 WO2011094150A1 (fr) 2010-01-27 2011-01-24 Thérapie antivirale

Publications (1)

Publication Number Publication Date
MA34002B1 true MA34002B1 (fr) 2013-02-01

Family

ID=44319704

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35145A MA34002B1 (fr) 2010-01-27 2011-01-24 Thérapie antivirale

Country Status (45)

Country Link
US (13) US20120295898A1 (fr)
EP (6) EP3351249A1 (fr)
JP (9) JP2013518107A (fr)
KR (4) KR101883750B1 (fr)
CN (2) CN105311033B (fr)
AP (1) AP3551A (fr)
AU (1) AU2011209788C1 (fr)
BR (1) BR112012018670A2 (fr)
CA (4) CA3003988C (fr)
CL (1) CL2012002080A1 (fr)
CO (1) CO6602152A2 (fr)
CR (1) CR20120423A (fr)
CY (6) CY1116509T1 (fr)
DK (4) DK3494972T3 (fr)
DO (2) DOP2012000205A (fr)
EA (4) EA032868B1 (fr)
EC (1) ECSP12012106A (fr)
ES (4) ES2969969T3 (fr)
FI (2) FI3494972T3 (fr)
FR (2) FR18C1043I2 (fr)
HK (1) HK1250335A1 (fr)
HR (4) HRP20240168T1 (fr)
HU (6) HUE026849T2 (fr)
IL (5) IL221007A (fr)
LT (5) LT2932970T (fr)
LU (2) LUC00090I2 (fr)
MA (1) MA34002B1 (fr)
ME (2) ME02182B (fr)
MX (4) MX2012008774A (fr)
MY (3) MY202778A (fr)
NO (2) NO2932970T3 (fr)
NZ (4) NZ627827A (fr)
PE (2) PE20160180A1 (fr)
PH (3) PH12012501537A1 (fr)
PL (4) PL3494972T3 (fr)
PT (4) PT2932970T (fr)
RS (4) RS57728B1 (fr)
SG (3) SG10201707183TA (fr)
SI (4) SI3127542T1 (fr)
SM (4) SMT201800290T1 (fr)
TN (1) TN2012000376A1 (fr)
TR (1) TR201807704T4 (fr)
UA (1) UA105556C2 (fr)
WO (1) WO2011094150A1 (fr)
ZA (1) ZA201205586B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351249A1 (fr) 2010-01-27 2018-07-25 VIIV Healthcare Company Thérapie antivirale
EP2911674A1 (fr) 2012-10-23 2015-09-02 Cipla Limited Composition pharmaceutique antirétrovirale
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
CA2897137A1 (fr) * 2013-02-18 2014-08-21 Ratiopharm Gmbh Forme galenique pharmaceutique solide de dolutegravir
EP2767272A1 (fr) * 2013-02-18 2014-08-20 Ratiopharm GmbH Forme posologique pharmaceutique solide de dolutegravir
DK3019503T3 (da) 2013-07-12 2017-11-20 Gilead Sciences Inc Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
NO2865735T3 (fr) 2013-07-12 2018-07-21
CA2924829C (fr) 2013-09-27 2019-10-29 Merck Sharp & Dohme Corp. Derives de quinolizine substitues utiles en tant qu'inhibiteurs de l'integrase du vih
WO2015140569A1 (fr) 2014-03-20 2015-09-24 Cipla Limited Composition pharmaceutique
JP6768522B2 (ja) 2014-06-04 2020-10-14 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
NO2717902T3 (fr) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3177629B1 (fr) 2014-07-29 2020-01-29 LEK Pharmaceuticals d.d. Nouveaux hydrates de sodium de dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CA2980362C (fr) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Composes carbamoylpyridones polycycliques et leur utilisation pharmaceutique
EP3334419A1 (fr) 2015-08-14 2018-06-20 Sandoz AG Composition pharmaceutique solide d'abacavir, de lamivudine et d'éfavirenz
WO2017205585A1 (fr) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinaisons, utilisations et traitements correspondants
WO2018028841A1 (fr) * 2016-08-12 2018-02-15 Sandoz Ag Composé pharmaceutique solide d'abacavir, de lamivudine et d'éfavirenz.
WO2018042332A1 (fr) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons, utilisations et traitements correspondants
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
WO2019016732A1 (fr) 2017-07-21 2019-01-24 Viiv Healthcare Company Régimes pour le traitement des infections du vih et du sida
JP2020528413A (ja) * 2017-07-21 2020-09-24 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
EP3694522B1 (fr) * 2017-10-13 2025-11-26 VIIV Healthcare Company Formulation de comprimé pharmaceutique bicouche
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
AU2020358156B2 (en) 2019-10-01 2024-06-06 Janssen Sciences Ireland Unlimited Company Method for treating HIV with cabotegravir and rilpivirine
US12678509B2 (en) 2019-11-08 2026-07-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (IAP) protein antagonists
WO2021142150A1 (fr) * 2020-01-09 2021-07-15 University Of Washington Combinaisons d'agents thérapeutiques à action prolongée et leurs procédés
EP4110783A1 (fr) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Composés tétracycliques pour le traitement d'une infection par le vih
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
CR20260070A (es) 2021-01-19 2026-04-24 Gilead Sciences Inc COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315)
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023164293A1 (fr) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Méthodes d'infections virales
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
KR20000022226A (ko) * 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
WO1999048371A1 (fr) 1998-03-27 1999-09-30 The Regents Of The University Of California Nouveaux inhibiteurs de vih integrase et traitement du vih fonde sur des combinaisons de medicaments contenant des inhibiteurs d'integrase
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
KR100880550B1 (ko) 2000-01-31 2009-01-30 쿠크 바이오텍, 인코포레이티드 판막 기구 및 심장 판막 기구
SI1762567T1 (sl) 2001-04-10 2012-08-31 Pfizer Derivati pirazola za zdravljenje HIV-a
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
BR0311141A (pt) 2002-06-27 2005-06-07 Medivir Ab Interação sinergìstica de abacavir e alovudine
PT1583542E (pt) * 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CN1976915A (zh) * 2004-02-11 2007-06-06 史密丝克莱恩比彻姆公司 Hiv整合酶抑制剂
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
SI1742642T1 (sl) * 2004-04-14 2009-04-30 Gilead Sciences Inc Fosfonatni analogi inhibitorskih spojin HIV integraze
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
ES2358269T3 (es) 2004-08-23 2011-05-09 Teva Pharmaceutical Industries Ltd Forma cristalina del ibandronato sódico y procedimientos para su preparación.
CA2577288C (fr) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AU2005305609B2 (en) 2004-09-17 2011-10-06 Idenix Pharmaceuticals, Inc. Phosphoindoles as HIV inhibitors
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
WO2006096444A2 (fr) 2005-03-04 2006-09-14 Smithkline Beecham Corporation Composes chimiques
DK3187225T3 (da) 2005-04-28 2022-02-28 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
JP2008542352A (ja) 2005-06-01 2008-11-27 ビオアリアンス ファルマ キノリン化合物及び他のｈｉｖ感染治療薬を含む相乗作用のコンビネーション
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
US20070219243A1 (en) 2005-12-30 2007-09-20 Kearney Brian P Method for improving the pharmacokinetics of HIV integrase inhibitors
AR059097A1 (es) * 2006-01-20 2008-03-12 Tibotec Pharm Ltd Tratamiento a largo plazo de la infeccion por vih
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
PT2069303E (pt) 2006-07-21 2016-06-08 Gilead Sciences Inc Inibidores de protease antiviral
ES2488922T3 (es) 2006-09-29 2014-09-01 Idenix Pharmaceuticals, Inc. Fosfoindoles enantiómeramente puros como inhibidores del HIV
TW200835693A (en) 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
CN101784532B (zh) 2007-06-29 2014-10-22 韩国化学研究院 Hiv逆转录酶抑制剂
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
KR20100040896A (ko) 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
HRP20131128T1 (hr) * 2007-07-12 2013-12-20 Janssen R&D Ireland Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
WO2009058923A1 (fr) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Antagonistes de ccr5 en tant qu'agents thérapeutiques
JP2011502998A (ja) 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
CA2711424A1 (fr) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Nouveaux derives de lupane
AU2008342536A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel C-21-keto lupane derivatives preparation and use thereof
PT2231628E (pt) 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規１７βルパン誘導体
WO2009148600A2 (fr) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Composés à base de lysine deutérée
WO2010011812A1 (fr) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Composés chimiques
EP3617194B1 (fr) 2008-12-11 2023-11-08 VIIV Healthcare Company Procédés et intermédiaires pour inhibiteurs de l'intégrase du vih de carbamoylpyridone
SG171308A1 (en) 2008-12-11 2011-07-28 Shionogi & Co Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
EP3351249A1 (fr) 2010-01-27 2018-07-25 VIIV Healthcare Company Thérapie antivirale
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
EP2590971A4 (fr) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc Composés utiles en tant qu'agents antiviraux, compositions, et procédés d'utilisation
RU2623039C2 (ru) 2011-04-01 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта

Also Published As

Publication number Publication date
HUE065569T2 (hu) 2024-06-28
ECSP12012106A (es) 2013-05-31
WO2011094150A1 (fr) 2011-08-04
JP2016145204A (ja) 2016-08-12
KR101964923B1 (ko) 2019-04-02
US20160339033A1 (en) 2016-11-24
MY207233A (en) 2025-02-07
NZ627824A (en) 2016-02-26
EA201290583A1 (ru) 2013-04-30
CY2018029I1 (el) 2019-07-10
MX356891B (es) 2018-06-19
NO2018036I1 (no) 2018-10-15
CY1121040T1 (el) 2019-12-11
KR101883750B1 (ko) 2018-07-31
IL257267A (en) 2018-03-29
TR201807704T4 (tr) 2018-06-21
DK2531027T3 (en) 2015-07-20
PT2531027E (pt) 2015-09-16
JP2021091705A (ja) 2021-06-17
ES2688925T3 (es) 2018-11-07
LT2932970T (lt) 2018-06-25
KR101830715B1 (ko) 2018-04-04
PL2531027T3 (pl) 2016-01-29
ME03058B (fr) 2019-01-20
US20170281636A1 (en) 2017-10-05
RS57728B1 (sr) 2018-12-31
JP2025131664A (ja) 2025-09-09
KR20170078868A (ko) 2017-07-07
CN102791129A (zh) 2012-11-21
AU2011209788A1 (en) 2012-08-16
CA3060290C (fr) 2022-07-12
MX367937B (es) 2019-09-12
HRP20181531T1 (hr) 2018-11-16
PE20121524A1 (es) 2012-12-03
EA201892277A1 (ru) 2019-03-29
US20160199379A1 (en) 2016-07-14
PL3127542T3 (pl) 2019-03-29
CY2024017I1 (el) 2025-05-09
ES2543066T3 (es) 2015-08-14
HUS2400017I1 (hu) 2024-06-28
CA2787691C (fr) 2018-07-17
SMT201500177B (it) 2015-09-07
JP2023085431A (ja) 2023-06-20
CA2967453A1 (fr) 2011-08-04
SMT201800290T1 (it) 2018-07-17
EP2932970A1 (fr) 2015-10-21
IL281959B (en) 2021-12-01
EP4316599A3 (fr) 2024-04-10
NZ627827A (en) 2016-02-26
LT3494972T (lt) 2024-03-12
MX2012008774A (es) 2012-08-17
JP6268386B2 (ja) 2018-01-31
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
CL2012002080A1 (es) 2012-11-30
HK1250335A1 (en) 2018-12-14
CN102791129B (zh) 2015-09-30
HUE037812T2 (hu) 2018-09-28
CY1120457T1 (el) 2019-07-10
EP2531027A4 (fr) 2013-07-03
CY1126771T1 (el) 2025-05-09
EP3127542B1 (fr) 2018-08-22
SI3127542T1 (sl) 2018-11-30
EP3494972A1 (fr) 2019-06-12
AU2011209788C1 (en) 2014-08-28
IL267658A (en) 2019-08-29
CA3060290A1 (fr) 2011-08-04
IL281959A (en) 2021-05-31
JP2022071126A (ja) 2022-05-13
PT3127542T (pt) 2018-11-26
SG10201707183TA (en) 2017-10-30
LTC2932970I2 (lt) 2022-04-25
RS54123B1 (sr) 2015-12-31
CA2967453C (fr) 2018-07-17
PH12012501537A1 (en) 2018-02-07
LUC00346I2 (fr) 2026-05-05
DK3494972T3 (da) 2024-01-29
FIC20240016I1 (fi) 2024-05-31
PH12016500195A1 (en) 2016-12-05
EP3494972B1 (fr) 2023-12-13
NZ627826A (en) 2016-01-29
EA037601B1 (ru) 2021-04-20
EA202190473A2 (ru) 2021-06-30
HUE026849T2 (en) 2016-08-29
US20150238496A1 (en) 2015-08-27
PT2932970T (pt) 2018-06-08
RS65183B1 (sr) 2024-03-29
ME02182B (me) 2015-10-20
US20200230147A1 (en) 2020-07-23
LUC00090I2 (fr) 2019-01-08
CA3003988A1 (fr) 2011-08-04
EA201690872A3 (ru) 2016-12-30
US20170216284A1 (en) 2017-08-03
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
LTPA2018013I1 (lt) 2018-11-12
TN2012000376A1 (en) 2014-01-30
LTPA2024516I1 (fr) 2024-06-25
EP2531027A1 (fr) 2012-12-12
JP2017008087A (ja) 2017-01-12
LUC00346I1 (fr) 2024-06-04
US20250017939A1 (en) 2025-01-16
KR20120128640A (ko) 2012-11-27
BR112012018670A2 (pt) 2018-02-06
EP4316599A2 (fr) 2024-02-07
HK1209629A1 (en) 2016-04-08
IL267658B (en) 2021-04-29
AP2012006445A0 (en) 2012-08-31
IL245182A0 (en) 2016-06-30
EP3351249A1 (fr) 2018-07-25
ES2969969T3 (es) 2024-05-23
AU2011209788B2 (en) 2014-02-06
CY2024017I2 (el) 2025-05-09
PL3494972T3 (pl) 2024-05-27
DK3127542T3 (en) 2018-11-12
PL2932970T3 (pl) 2018-08-31
EA025176B1 (ru) 2016-11-30
FI3494972T3 (fi) 2024-03-01
DOP2021000147A (es) 2022-01-16
US10426780B2 (en) 2019-10-01
PT3494972T (pt) 2024-02-12
PH12016500195B1 (en) 2021-08-04
EA202190473A3 (ru) 2021-12-31
MX367938B (es) 2019-09-12
HUS1800042I1 (hu) 2018-11-28
CY1116509T1 (el) 2017-03-15
CN105311033B (zh) 2019-05-07
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
US20170079982A1 (en) 2017-03-23
CY2018029I2 (el) 2019-07-10
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
EP2932970B1 (fr) 2018-03-21
JP7724619B2 (ja) 2025-08-18
MY202778A (en) 2024-05-21
SMT202400063T1 (it) 2024-03-13
PH12018502489A1 (en) 2020-06-15
DOP2012000205A (es) 2012-10-15
CO6602152A2 (es) 2013-01-18
US20180200254A1 (en) 2018-07-19
CR20120423A (es) 2012-11-22
KR20160111536A (ko) 2016-09-26
DK2932970T3 (en) 2018-05-28
KR20180078358A (ko) 2018-07-09
MY188334A (en) 2021-11-30
NZ601319A (en) 2014-08-29
FR24C1024I2 (fr) 2025-06-27
HRP20180855T1 (hr) 2018-06-29
SI3494972T1 (sl) 2024-03-29
JP2013518107A (ja) 2013-05-20
CA3003988C (fr) 2020-01-07
EP3127542A1 (fr) 2017-02-08
US11234985B2 (en) 2022-02-01
CA2787691A1 (fr) 2011-08-04
IL221007A0 (en) 2012-09-24
FR18C1043I1 (fr) 2018-11-30
JP2019167371A (ja) 2019-10-03
LTC3494972I2 (fr) 2025-11-10
ES2670811T3 (es) 2018-06-01
US20180098992A1 (en) 2018-04-12
HUE040554T2 (hu) 2019-03-28
HK1179522A1 (en) 2013-10-04
HRP20150770T1 (hr) 2015-08-28
SG10201509476RA (en) 2015-12-30
SI2531027T1 (sl) 2015-08-31
JP2018127473A (ja) 2018-08-16
US20210401850A1 (en) 2021-12-30
FR18C1043I2 (fr) 2019-10-11
AP3551A (en) 2016-01-18
SI2932970T1 (en) 2018-07-31
LT3127542T (lt) 2018-11-26
EP2531027B1 (fr) 2015-05-06
IL245182B (en) 2018-04-30
EA201690872A2 (ru) 2016-08-31
EA032868B1 (ru) 2019-07-31
UA105556C2 (uk) 2014-05-26
NO2932970T3 (fr) 2018-08-18
US20120295898A1 (en) 2012-11-22
US20170119777A1 (en) 2017-05-04
SMT201800594T1 (it) 2019-01-11
CN105311033A (zh) 2016-02-10

Similar Documents

Publication Publication Date Title
CO6602152A2 (es) En respuesta al requerimiento de pago de reivindicaciones adicionales a las 10 primeras,presenta nuevo capítulo reivindicatorio y paga.
MA44674A (fr) Inhibiteurs de bromodomaine
MA34170B1 (fr) Inhibiteurs de transcriptase inverse non nucléosidiques
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA39721A (fr) Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
DE60318891D1 (de) Cyclopropylverbindungen als ccr5 antagonisten
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
MA38182A1 (fr) Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
MY186986A (en) Compositions and methods of use of phorbol esters
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
EP2555798A4 (fr) Procédés et compositions pour l'inhibition de la transmission du vih
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
TW200738700A (en) HIV integrase inhibitors
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales